DATASPARK/OOREDOO
29.6.2021 02:02:07 CEST | Business Wire | Press release
DataSpark has signed a multi-year strategic deal with communications giant, Ooredoo Group, to automate and standardise their group-wide network planning processes, optimise capital expenditure spending and deliver superior customer experience.
The agreement will see DataSpark introduce its state-of-the-art Smart Network Planning (SNP) product to help establish an advanced analytics platform and capability in network planning across all 10 Ooredoo Group operating companies around the world.
The SNP solution (also referred to as CAPEX Optimizer in some regions) will deliver cost and operational efficiencies for Ooredoo Group’s network expansion investments while ensuring that fast-evolving customer needs are always kept at the centre of decision making.
The product utilises advanced machine learning methodologies to forecast and anticipate network capacity and throughput ahead of time, enabling Ooredoo to direct its capital expenditure in a way that creates the most value for the end customer.
DataSpark Chief Operating Officer, Shaowei Ying, said the partnership is a testament to DataSpark’s ability to provide performance-driven analytics solutions for global telco providers.
“The SNP solution empowers Ooredoo’s operating companies to have an automated, data-driven and customer-centric approach to their radio network capacity planning. It leverages best-in-class technologies that DataSpark developed over the last decade to process data at scale and extract granular insights for decision optimisation,” said Mr Ying. “We welcome this landmark partnership with Ooredoo Group which represents a significant milestone. DataSpark, as part of NCS NEXT, will continue expanding telco-centric analytic solutions and collaborate with telecommunication clients globally.”
The SNP’s application for telcos is founded on several key factors including automated and cost-efficient network planning through customer experience, services and network metrics, and layered analytics to inform accurate network investment decisions.
Ooredoo Group Chief Technology and Information Officer, Nigel Thomas Byrne, said the company’s venture with DataSpark would help ensure visibility and standardisation into network planning activities across the Ooredoo Group. This will also help in sharing network planning best practices across the group and further strengthen the culture of data-driven decision making.
“The insights and recommendations delivered through DataSpark’s SNP solution will provide cost-optimisation and allow us to innovate with our networks, ultimately enhancing the customer experience,” said Mr Byrne. “Our mission to deliver superior service is predicated on high-performance network planning and capacity management, and SNP’s advanced analytics will help us make informed decisions to deliver on this goal.”
DataSpark’s mobility data products are designed to optimise telco network solutions for revenue growth and improve customer satisfaction. DataSpark empowers organisations with mobility intelligence to help maximise the value of their networks and save on capital investment spending. Existing telecommunication clients include Singtel, Optus, Advanced Info Service and Globe Telecom.
About DataSpark: DataSpark are leaders in processing large geospatial temporal mobility data to deliver intelligence on people and places using the highest data privacy standards. Understanding how people move, where they go and what they do enables organisations to make more informed decisions from planning capital expenditure to creating better customer experiences. DataSpark (known as DSpark in Australia) is part of the NCS Group with offices across Australia, Singapore, the Philippines, and Indonesia. For more information, visit dsanalytics.com .
About NCS: NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of applications, infrastructure and engineering. For more information, visit ncs.com.sg .
About Ooredoo: Ooredoo is a leading international communications company delivering mobile, fixed, broadband internet and corporate managed services tailored to the needs of consumers and businesses across markets in the Middle East, North Africa and Southeast Asia. For more information, visit ooredoo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom